Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-08-07
2007-08-07
Wax, Robert A. (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S363000
Reexamination Certificate
active
10934401
ABSTRACT:
A modified serum albumin is provided which has been modified in the n-terminal region or binding region VI, such as through a truncation of at least three amino acids at the n-terminal end, so that it exhibits reduced or eliminated binding of trace metals such as nickel and/or copper. Other suitable modifications to this binding region include mutations such as an elongation or insertion which will be sufficient to disrupt the trace metal binding which is highest at this site. The modified albumin of the present invention is advantageous in that its binding to trace metals is reduced or eliminated, and it can thus be used more safely and effectively than unmodified albumin with a reduced or eliminated likelihood of causing an allergic reaction to the trace metal in the human being treated with the albumin composition.
REFERENCES:
patent: 6475743 (2002-11-01), Bar-Or et al.
patent: 2003/0180820 (2003-09-01), Bar-Or et al.
patent: 0 180 968 (1986-05-01), None
patent: 0 244 859 (1987-11-01), None
patent: WO 00/20454 (2000-04-01), None
patent: WO 01/91713 (2001-06-01), None
patent: WO 02/05645 (2002-01-01), None
patent: WO 02/49671 (2002-06-01), None
D.C. Carter et al., “Structure of Serum Albumin,” Advances in Protein Chemistry, 1994, vol. 45, pp. 153-203.
Takhashi et al., “Structural changes and metal binding by proalbumins and other amino-terminal . . . ”, Proceedings of the National Academyy of Sciences, vol. 84, Nov. 1987, pp. 7403-7407.
Bar-Or et al., “Characterization of the CO2+ and NI2+ Binding Amino-Acid Residues . . . ”, European Journal of Biochemistry, vol. 268, No. 1, Jan. 2001, pp. 42-47.
Database WPI, Derwent Publications, SHAN—1995-200996, Apr. 20, 1994.
Chan et al., “Site-specific N-terminal auto-degradation of human serum albumin”, European Journal of Biochemistry, vol. 227, No. 1-2, 1995, pp. 524-528.
Sadler et al., Involvement of a lysine residue in the N-terminal Ni2+ and Cu2+ binding site of serum albumins, European Journal of Biochemistry, vol. 220, No. 1, 1994, pp. 193-200.
New Century Pharmaceuticals Inc.
Schulman B. Aaron
Stites & Harbison PLLC
Wax Robert A.
LandOfFree
Modified serum albumin with reduced affinity for nickel and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modified serum albumin with reduced affinity for nickel and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modified serum albumin with reduced affinity for nickel and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3861315